Metsera (NASDAQ:MTSR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($3.52) earnings per share for the quarter, Zacks reports.
Metsera Price Performance
Shares of NASDAQ MTSR opened at $28.11 on Thursday. Metsera has a 1-year low of $23.08 and a 1-year high of $32.81.
Analyst Ratings Changes
A number of brokerages recently issued reports on MTSR. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Guggenheim started coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective for the company. Bank of America began coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price on the stock. Finally, Evercore ISI initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company.
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
- Five stocks we like better than Metsera
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 4 Reasons Amazon Stock Can’t Be Ignored Right Now
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Intel’s Strategy to Win the Next AI Frontier
- How to Calculate Stock Profit
- 2 Stocks With Strong Fundamentals Gaining Technical Momentum
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
